SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093948
Filing Date
2024-08-08
Accepted
2024-08-08 16:10:27
Documents
77
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnth-20240630.htm   iXBRL 10-Q 1736729
2 EX-10.1 dnth-ex10_1.htm EX-10.1 71968
3 EX-31.1 dnth-ex31_1.htm EX-31.1 16762
4 EX-31.2 dnth-ex31_2.htm EX-31.2 16835
5 EX-32.1 dnth-ex32_1.htm EX-32.1 14906
  Complete submission text file 0000950170-24-093948.txt   8382438

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20240630.xsd EX-101.SCH 1374770
79 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20240630_htm.xml XML 1417605
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38541 | Film No.: 241188380
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)